海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Study of the effect of pregnancy on the concentrations of antiretroviral drugs in the blood of women with HIV infection
- HIV-1 infection MedDRA version: 14.1 Level: LLT Classification code 10008922 Term: Chronic infection with HIV System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Italy
- 2012-03-02
Authorised
- A study to evaluate how different combinations of antiviral agents, when given with standard medicines, affect the treatment outcome of patients infected with the Hepatitis C Virus (HCV).
- Genotype 1 Hepatitis C Virus Infection MedDRA version: 13.1 Level: SOC Classification code 10021881 Term: Infections and infestations System Organ Class: 10021881 - Infections and infestations MedDRA version: 13.1 Level: PT Classification code 10019744 Term: Hepatitis C System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Czech Republic, Germany, Hungary, Italy, New Zealand, United Kingdom, United States
- 2011-05-27
Authorised
- A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease
- Subjects with Moderately-to-Severely Active Crohn’s Disease MedDRA version: 14.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Spain, Sweden, United Kingdom, United States
- 2010-10-12
Authorised
- The effect of bezafibrate on itch in a subset of liver diseases
- Primary biliary cirrhosis (PBC) Primary sclerosing cholangitis (PSC) Secondary sclerosing cholangitis (SSC);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Netherlands, Spain
- 2017-10-10
Authorised
- Optimisation of follicular recruitment in IVM cycles
- Infertile patients with polycystic ovaries MedDRA version: 20.0 Level: LLT Classification code 10065161 Term: Polycystic ovarian syndrome System Organ Class: 100000019245 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
- Belgium
- 2017-08-14
Authorised
- A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase
- Primary Biliary Cholangitis MedDRA version: 20.0 Level: LLT Classification code 10036680 Term: Primary biliary cirrhosis System Organ Class: 100000023866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Belgium, Canada, Germany, Greece, Israel, Italy, Spain, United Kingdom, United States
- 2017-07-04
Authorised
- Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma
- Cohort 1: Subjects with desmoid tumor Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2016-12-27
Authorised
- MAVMET: A research study exploring whether MAraViroc, a licensed treatment for HIV infection and METformin, a licensed treatment for diabetes, are effective and safe at reducing the amount of fat in the liver.
- Hepatic steatosis in adults with chronic HIV-1 infection MedDRA version: 20.1 Level: PT Classification code 10029530 Term: Non-alcoholic fatty liver System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- United Kingdom
- 2018-05-09
Authorised
- Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity
- 1. Obesity 2. Diabetes Mellitus, Type 2 MedDRA version: 20.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Algeria, Argentina, Canada, European Union, Greece, India, Japan, Russian Federation, South Africa, United Arab Emirates, United States
- 2018-04-23
Authorised
- Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity
- 1. Obesity 2. Diabetes Mellitus, Type 2 MedDRA version: 20.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Algeria, Argentina, Canada, European Union, Greece, India, Japan, Russian Federation, South Africa, Spain, United Arab Emirates, United States
- 2018-03-07
Authorised
- Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-02-01
Authorised
- Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-02-01
Authorised
- Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Moldova, Republic of, New Zealand, Norway, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-01-31
Authorised
- Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-01-30
Authorised
- Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Australia, Austria, Bulgaria, Canada, China, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Korea, Republic of, Lithuania, Mexico, Netherlands, Poland, Portugal, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Turkey, Ukraine, United States
- 2018-01-29
Authorised
- A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s disease
- Treatment of moderate, active Crohn’s disease: induction of remission. MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease
- France, Germany, Hungary, Italy
- 2007-06-01
Authorised
- RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NNRTI-TRIPLE THERAPY BASED-REGIMENS.
- HIV-1 infection MedDRA version: 9 Level: LLT Classification code 10008919 Term: Chronic HIV infection
- Spain
- 2009-07-14
Authorised
- Hyperoxic exercise training as an innovative therapy to improve metabolic control, endothelial dysfunction and physical fitness in deconditioned type 2 diabetes patients - Hyperoxic Exercise in Type 2 Diabetes
- insulin resistance, endothelial dysfunction, cardiovascular fitness, lipid metabolism and glycemic control in deconditioned non-insulin dependent type 2 diabetes patients MedDRA version: 9.1 Level: PT Classification code 10050322 Term: Oxygen supplementation
- Netherlands
- 2009-05-25
Authorised
- Evaluation chez l’enfant et l’adulte présentant une rechute d’ostéosarcome de l’efficacité et de la tolérance d’un traitement adjuvant par Thiotépa® haute dose associé à une chimiothérapie conventionnelle. - OSII-TTP
- Adultes et enfants, âgés de 1 à 50 ans, atteints d'ostéosarcome en 1ère rechute locale ou métastatique (ou en 2ème rechute après traitement de la 1ère rechute par chirurgie seule), dont une résection chirurgicale complète de toutes les localisations est envisageable d’emblée ou après chimiothérapie. MedDRA version: 9.1 Level: LLT Classification code 10031296 Term: Osteosarcoma recurrent
- France
- 2009-03-24
Authorised
- Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST - FAST VERSION
- This is a open label, prospective, multicenter trial in patients recieving one hour infusions of infliximab (i.e. Remicade)as part of their daily practice. Main objective: Is to assess the tolerability of Remicade with an infusionsrate of 30 minutes. Patients: eligible patients are those with intestinal fistulas Mb Crohn disease or Ulcerative colitis/IBD. or patietns with
- Sweden
- 2009-03-02
